Table 1 Differential expressed circulating microRNAs of ovarian cancer in profiling studies

miR-21, 29a, 92, 93, 126

miR-127, 155, 99b

ovarian cancer

serum, patient vs. normal control

microarray,qRT-PCR

Resnick, 2009 [14]

95 miRNAs

88 miRNAs, 4 validated by qRT-PCR: miR-132, 26a, let-7b, miR-145

serous ovarian cancer

serum, patient vs. healthy control

microarray,qRT-PCR

Chung, 2013 [15]

miR-205, 643, 200a, 184, 9, 21*, let-7f-2*, miR-483-5p, 616*, 34a*, 501-5p, 141

let-7a, 7d*, 7e*, 106b*, 149, 193b*, 362-3p, 363*, 422a, 449a, 770-5p, 98, 15b*, let-7f, miR-221, 450a, 570, 573

lower let-7f vs. poor prognosis

epithelial ovarian cancer

plasma, patient vs. healthy control

TaqMan Low Density Array, qRT-PCR

Zheng, 2013 [18]

miR-1274a, 30b, 30c, 625-3p, 720;

serous epithelial ovarian cancer

plasma, OC^# patient vs. healthy volunteer

TaqMan Open Array

miR-106b, 126, 150, 17, 20a, 92a;

plasma, OC^# patient vs. benign neoplasm

Shapira, 2014 [16]

MiR-139-5p, 142-3p, 484, 486, 660

benign neoplasm vs. healthy volunteer

miR-21, 191, 16, 15b, 1977, 1979, 1973, 1974, 4284, 195;

EAOC^##: endometrioidand/or clear cell adenocarcinoma

plasma, EAOC patients vs. healthy controls

RT-qPCR

Suryawanshi, 2013 [17]

miR-362-5p, 1274a, 21, 766, 1975, 1308, 191, 744, 376a, 1246;

plasma, EAOC patients vs. endometriosis patients

miR-16, 195, 191, 1974, 4284, 15b, 1978, 1979, 362-5p, 1973

endometriosis patients vs. healthy controls